BIOSTATISTICS CORE

生物统计学核心

基本信息

批准号：
7678600
负责人：
Glenn Heller
金额：
$ 15.22万
依托单位：
SLOAN-KETTERING INST CAN RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/7678600
关键词：
17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin 70-kDa Ribosomal Protein S6 Kinases Address Adjuvant Affect African American Age Alleles Am 80 American Analysis of Variance Androgen Receptor Animal Model Animals Ansamycin Antineoplastic Antibiotic Antibodies Antigens Apoptosis Archives Area Attenuated Binding Biological Assay Biological Markers Biology Biometry Biopsy Biopsy Specimen Biostatistics Core Blood Blood specimen Boxing British CD4 Positive T Lymphocytes CD8B1 gene CTLA4 gene Cancer Patient Carboplatin Caucasoid Race Cell Line Cells Cessation of life Chemoprevention Chemopreventive Agent Child Chromosome abnormality Chromosomes Class Classification Clinical Clinical Research Clinical Trials Code Cohort Studies Combined Modality Therapy Commit Comparative Study Condition Confidence Intervals Control Groups Core Facility Correlative Study Cox Models Cox Proportional Hazards Models Cytotoxic T-Lymphocyte-Associated Protein 4 Cytotoxic T-Lymphocytes DNA DNA Vaccines Data Data Analyses Data Set Development Diagnostic Disease Disease regression Disseminated Malignant Neoplasm Dose Dose-Limiting Drug Combinations Drug Kinetics End Point Enrollment Ensure Event Exhibits Experimental Designs Family Fishes Flow Cytometry Freedom Frequencies Funding Gene Frequency Genes Genetic Genetic Polymorphism Genotype Gleason Grade for Prostate Cancer Glutamate Carboxypeptidase II Goals Gray unit of radiation dose HLA-DR Antigens Half-Life Haplotypes Harvest Heat-Shock Proteins 90 Hormones Image Immune response Immunohistochemistry Immunologics Immunology Immunotherapy In Vitro Individual Inequality Infusion procedures Institutes Institution Interleukin-12 Investigation KLK3 gene Knockout Mice LNCaP Laboratories Left Lesion Linkage Disequilibrium Local Therapy Localized Logic Logistic Regressions Longitudinal Studies Lymphocyte MDM2 gene MDM2 gene Maintenance Malignant Neoplasms Malignant neoplasm of prostate Malignant neoplasm of testis Measures Memorial Sloan-Kettering Cancer Center Metastatic Prostate Cancer Methodology Methods Minor Modality Modeling Modification Molecular Molecular Genetics Morbidity - disease rate Mus Mutation Nature Neoplasm Metastasis Nomograms Numbers Odds Ratio Oncogenes Operative Surgical Procedures Other Genetics Outcome PC3 cell line PSA level Pain Parents Pathological Staging Pathology Pathway interactions Patient observation Patients Pattern Peptides Performance Peripheral Blood Lymphocyte Personal Satisfaction Pharmaceutical Preparations Phase Phase I Clinical Trials Phase II Clinical Trials Pilot Projects Placebos Plasma Population Population Study Positioning Attribute Positron-Emission Tomography Preclinical Testing Probability Procedures Process Programming Languages Progression-Free Survivals Prostate Prostatectomy Prostatic Neoplasms Protein Overexpression Proteins Proteomics Purpose Race Radiation Radical Prostatectomy Randomized Rate Receiver Operating Characteristics Recruitment Activity Regression Analysis Relative (related person)Relative Risks Reproducibility Reproduction spores Research Research Design Research Infrastructure Research Methodology Research Personnel Research Project Grants Resistance Rifabutin Risk Role SNP genotyping Safety Sample Size Sampling Schedule Scheme Scientist Score Screening procedure Selection for Treatments Series Serum Side Significance Level Simulate Specimen Staging Staining method Stains Standards of Weights and Measures Statistically Significant Structure Study Section Sum Survival Analysis System T-Lymphocyte TNFRSF5 gene TP53 gene Testing Therapeutic Therapeutic Intervention Time Tissue Microarray Tissue Sample Tissues Toxic effect Training Transgenic Mice Transgenic Organisms Translational Research Treatment Protocols Tumor Immunity Tumor Suppressor Proteins Tumor Volume Upper arm Vaccine Adjuvant Vaccines Validation Vorinostat Week Work Xenograft procedure age group anticancer research base carcinogenesis career case control caucasian American chemotherapy clinical Diagnosis clinical effect clinical efficacy clinically significant cohort compare effectiveness cytokine day design docetaxel experience follow-up hazard human FRAP1 protein human disease immunogenic improved inhibitor/antagonist interest markov model men molecular modeling mortality mouse model multidisciplinary novel novel diagnostics novel therapeutics outcome forecast pre-clinical preclinical study predictive modeling programs research study response segregation senescence size small molecule statistics success tau Proteins tool treatment effect tumor tumor growth tumorigenic uptake vaccine evaluation vector

项目摘要

DESCRIPTION (provided by applicant): The MSKCC SPORE in Prostate Cancer, initially funded in 2001, focused on four broad translational research goals: (1) to develop better predictive models of prognosis for localized prostate cancer incorporating validated molecular markers to improve treatment selection; (2) to identify critical molecular and genetic mechanisms of prostate carcinogenesis, progression, and metastasis; (3) to develop PSMA- targeted DMA vaccines for men with rising PSA after local therapy; and (4) to develop new mechanism- based drugs for castrate-resistant metastatic cancers. With strong support from the SPORE and our institution, we have made considerable progress. We have completed a long-term study of watchful waiting in a large British cohort and have collected diagnostic biopsy specimens as tissue microarrays for marker analyses. We have created more than a dozen new animal models of prostate cancer that mimic the human disease, and identified and validated predictive molecular markers. We have documented the efficacy of a PSMA DNA vaccine in a phase 1 clinical trial. And we have demonstrated that Hsp90 targeted therapy with ansamycin degrades the androgen receptor and is active against castrate metastatic prostate cancer. We now have in place an experienced, productive multidisciplinary team of investigators committed to translational research in prostate cancer, a large patient population amenable to participation in clinical trials, and superb infrastructure to support such trials. With a large cadre of scientists exploring the biology of prostate cancer and developing new therapeutic strategies, we have a healthy pipeline of new ideas ripe for investigation as diagnostic and therapeutic interventions. In preparing our SPORE for the next cycle, we have retained the overall objectives and the four major research projects, which function as flexible, multidisciplinary programs where we are able to shift emphasis to the most promising areas of research within the framework of original goals as new information emerges. We have added one new project, Checkpoint Blockade in Immunotherapy of Prostate Cancer, by James Allison, recently recruited here as Chair of Immunology. We will retain five cores (Biospecimen, Biostatistics, Animal Models, Animal Imaging, and Administration) and discontinue the DNA Array Core, replaced by the MSKCC core facility. Career Development has successfully recruited four new translational investigators to our SPORE, and Developmental Research has funded ten pilots with over $1.8 million in additional institutional support, several of which have achieved independent funding. Our investigators collaborate successfully with other SPOREs in Prostate Cancer and institutions and they have been among the leaders in inter-SPORE clinical trials and the pilot National Biorepository Network. With continued support the MSKCC SPORE is well positioned to move novel diagnostic and therapeutic interventions rapidly from the laboratory to the human disease with the goal of reducing morbidity and mortality from prostate cancer.

描述（由申请人提供）：前列腺癌 MSKCC SPORE 最初于 2001 年资助，重点关注四个广泛的转化研究目标：(1) 开发更好的局限性前列腺癌预后预测模型，结合经过验证的分子标志物以改善治疗选择； (2) 确定前列腺癌发生、进展和转移的关键分子和遗传机制； (3) 为局部治疗后 PSA 升高的男性开发 PSMA 靶向 DMA 疫苗； (4)开发针对去势抵抗性转移癌的新机制药物。在SPORE和我们机构的大力支持下，我们取得了长足的进步。我们已经在英国大型队列中完成了一项观察等待的长期研究，并收集了诊断活检标本作为组织微阵列用于标记分析。我们创建了十多种模拟人类疾病的新前列腺癌动物模型，并鉴定和验证了预测分子标记。我们已经在一期临床试验中记录了 PSMA DNA 疫苗的功效。我们已经证明，安莎霉素 Hsp90 靶向治疗可降解雄激素受体，并且对去势转移性前列腺癌具有活性。我们现在拥有一支经验丰富、富有成效的多学科研究团队，致力于前列腺癌的转化研究，有大量愿意参与临床试验的患者群体，以及支持此类试验的一流基础设施。随着一大批科学家探索前列腺癌的生物学并开发新的治疗策略，我们拥有了一系列健康的新想法，可供研究作为诊断和治疗干预措施。在为下一个周期准备 SPORE 时，我们保留了总体目标和四个主要研究项目，这些项目作为灵活的多学科计划，使我们能够在最初目标的框架内将重点转移到最有前途的研究领域：新信息出现。我们增加了一个新项目，即前列腺癌免疫治疗中的检查点封锁，由 James Allison 负责，他最近被任命为免疫学系主任。我们将保留五个核心设施（生物样本、生物统计学、动物模型、动物成像和管理），并停止使用 DNA 阵列核心设施，取而代之的是 MSKCC 核心设施。职业发展已成功为我们的 SPORE 招募了四名新的转化研究者，发展研究已为 10 名试点项目提供了超过 180 万美元的额外机构支持，其中一些项目已获得独立资助。我们的研究人员与前列腺癌和机构中的其他 SPORE 成功合作，他们一直是 SPORE 间临床试验和试点国家生物样本库网络的领导者之一。在持续的支持下，MSKCC SPORE 完全有能力将新型诊断和治疗干预措施从实验室快速转移到人类疾病，以降低前列腺癌的发病率和死亡率。